Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer

详细信息    查看全文

• 作者：Eleni Gourni ; Luigi Del Pozzo ; Emilie Kheirallah ; Christiane Smerling ; Beatrice Waser ; Jean-Claude Reubi ; Brett M. Paterson ; Paul S. Donnelly ; Philipp T. Meyer ; Helmut R. Maecke
• 刊名：Molecular Pharmaceutics
• 出版年：2015
• 出版时间：August 3, 2015
• 年：2015
• 卷：12
• 期：8
• 页码：2781-2790
• 全文大小：434K
• ISSN：1543-8392

文摘

The gastrin-releasing peptide receptor (GRPr) is an important molecular target for the visualization and therapy of tumors and can be targeted with radiolabeled bombesin derivatives. The present study aims to develop statine-based bombesin receptor antagonists suitable for labeling with ⁶⁴Cu for imaging by positron emission tomography (PET). The potent GRPr antagonist d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH₂ was conjugated to the sarcophagine (3,6,10,13,16,19-hexaazabicyclo[6.6.6] icosane = Sar) derivative 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid (MeCOSar) via PEG4 (LE1) and PEG2 (LE2) spacers and radiolabeled with ⁶⁴Cu²⁺ with >95% yield and specific activities of about 100 MBq/nmol. Both Cu(II) conjugates have high affinity for GRPr (IC₅₀: ^natCu-LE1, 1.4 卤 0.1 nM; ^natCu-LE2, 3.8 卤 0.6 nM). The antagonistic properties of both conjugates were confirmed by Ca²⁺-flux measurements. Biodistribution studies of Cu-64-LE1 exhibited specific targeting of the tumor (19.6 卤 4.7% IA/g at 1 h p.i.) and GRPr-positive organs. Biodistribution and PET images at 4 and 24 h postinjection showed increasing tumor-to-background ratios with time. This was illustrated by the acquisition of PET images showing high tumor-to-normal tissue contrast. This study demonstrates the high affinity of the MeCOSar-PEGx-bombesin conjugates to GRPr. The stability of ⁶⁴Cu complexes of MeCOSar, the long half-life of ⁶⁴Cu, and the suitable biodistribution profile of the ⁶⁴Cu-labeled peptides lead to PET images of high contrast suitable for potential translation into the clinic.